Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,461
datasets available to search
ShareScore release 0.9.0
Dataset results
2,461 results for “Rheumatoid Arthritis”
Safety, Efficacy, and Pharmacokinetics of Adalimumab in Japanese Children With Juvenile Rheumatoid Arthritis
ClinicalTrials.gov study NCT00690573. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Rituximab for the Treatment of Early Rheumatoid Arthritis (RA)
ClinicalTrials.gov study NCT00396812. IPD Sharing: Not stated. Countries: 1. Publications: 4.
A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Th
ClinicalTrials.gov study NCT02001987. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF Inhibitor.
ClinicalTrials.gov study NCT00502840. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.
ClinicalTrials.gov study NCT00462345. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants
ClinicalTrials.gov study NCT02573012. IPD Sharing: Not stated. Countries: 6. Publications: 1.
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice
ClinicalTrials.gov study NCT01474291. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis
ClinicalTrials.gov study NCT03691909. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study to Evaluate the Safety and Efficacy of VIB4920 in Participants With Rheumatoid Arthritis
ClinicalTrials.gov study NCT04163991. IPD Sharing: NO. Countries: 2. Publications: 1.
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor
ClinicalTrials.gov study NCT01350804. IPD Sharing: Not stated. Countries: 15. Publications: 2.
Progression to rheumatoid arthritis in at-risk individuals is defined by systemic inflammation and by T and B cell dysregulation
Open the record for dataset details and reuse information.
Data from: Large-scale meta-analysis on rheumatoid arthritis across East Asian and European populations
Open the record for dataset details and reuse information.
Data from: Multi-omics analyses on rheumatoid arthritis in CD4+ T cells
Open the record for dataset details and reuse information.
Association between exposure to ecotoxicants and clinical and laboratory indices at clinical and preclinical stages of rheumatoid arthritis
Open the record for dataset details and reuse information.
Data underlying Frailty in people with rheumatoid arthritis – A systematic review of observational studies
<p>Abstract screening results, full text screening results, and data extraction documents for Frailty in people with rheumatoid arthritis – A systematic review of observational studies</p>
Clinical Dataset for the Paper 'Machine Learning Prediction of Treatment Response to Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis'
<p>This dataset accompanies the manuscript titled "Machine Learning Prediction of Treatment Response to Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis." It includes clinical data used for training and evaluating the machine learning models described in the paper. The dataset contains baseline clinical data of 154 RA patients who were treated with bDMARDs. The labels for remission, and effectiveness (remission and low disease activity) were applied after a 6-month follow-up based on EULAR criteria on DAS28ESR. The sustained effectiveness label indicates maintaining effectiveness within 6 months after initially achieving effectiveness.</p> <p><strong>Crossponder Authors:</strong></p> <ul> <li>Fatemeh Salehi (email: <a rel="noreferrer">fatemeh.salehihafshejni@fau.de</a>)</li> </ul>
FIGURES 1–2 in High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis.
FIGURES 1–2. Helichus cordubensis: 1, male genitalia, ventral view; 2, lateral view of same. Locality of specimen used for the illustration: "Alta Gracia, La Granja. Sierra de Córdoba, Cordoba province, Argentina".
Identification and evaluation of serum protein biomarkers which differentiate psoriatic from rheumatoid arthritis
<p><span><b>Objectives</b></span></p> <p><span>To identify serum protein biomarkers which might separate early inflammatory arthritis (EIA) patients with psoriatic arthritis (PsA) from those with rheumatoid arthritis (RA) and may be used to support appropriate early intervention. </span></p> <p><span><b>Methods</b></span></p> <p><span>The serum proteome of patients with PsA and RA was interrogated using liquid chromatography mass spectrometry (LC-MS/MS) (n=64 patients), a multiplexed antibody assay (Luminex) for 48 proteins (n=64 patients) and an aptamer-based assay (SOMAscan) targeting 1,129 proteins (n=36 patients). Multiple reaction monitoring assays were developed to evaluate the performance of putative markers in the discovery cohort (n=60) as well as an independent cohort of PsA and RA patients (n=167). </span></p> <p><span><b>Results</b></span></p> <p><span>Multivariate analysis of the protein discovery data revealed that it was possible to discriminate PsA from RA patients with an area under the curve (AUC) of 0.94 for nLCMS/MS, 0.69 for Luminex based measurements; 0.73 for SOMAscan analysis. Random forest models confirmed that a subset of protein measured by MRM could differentiate PsA and RA patients with an AUC of 0.79 and 0.85 during separate evaluation and verification studies. </span></p> <p><span><b>Conclusion</b></span></p> <p><span>We report a serum protein biomarker panel which can separate EIA patients with PsA from those with RA. We suggest that the routine use of such a panel in EIA patients will improve clinical decision making. With continued evaluation and refinement on additional and larger patient cohorts including those with other arthropathies we suggest the panel identified here will contribute toward improved clinical decision making.</span></p>
Fig. 7 in Sesquiterpenes from Kadsura coccinea attenuate rheumatoid arthritis-related inflammation by inhibiting the NF-κB and JAK2/STAT3 signal pathways
Fig. 7. Experimental validation of the representative signaling pathways in vitro. Compound 19 inhibited the NF-kB (A) and JAK2/STAT3 (B) signaling pathways in RAW 264.7 cells induced by LPS. #p <0.05 compared with control group. *p <0.05, **p <0.01 compared with model group.
Fig. 6 in Sesquiterpenes from Kadsura coccinea attenuate rheumatoid arthritis-related inflammation by inhibiting the NF-κB and JAK2/STAT3 signal pathways
Fig. 6. (A) The gene ontology (GO) enrichment analysis for potential targets. (B) The KEGG pathway enrichment analysis of potential targets. (C) The drugcompound-target-pathway (D-C-T-P) network established by Cytoscape V 3.6.0. The red node represents K. coccinea, the yellow represents active compounds, the blue nodes represent targets, and the green nodes represent the pathways. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.